Testing version — LOERadar is in active testing. Features and data may change.
BIXLENVO (BICTEGRAVIR AND LENACAPAVIR) | LOERadar
Not in the current Orange Book— This application is not listed in FDA's current Orange Book data files (no listed patents or exclusivities). Product and approval data shown are from FDA's Drugs@FDA database.
BIXLENVO
NDANot in Orange Book
BICTEGRAVIR AND LENACAPAVIR | N221104 | GILEAD SCIENCES
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 75MG;50MG
▴
TABLET; ORAL | Approved: Aug. 27, 2026
No patent or exclusivity listings for this strength.